Doongaji D R, Sheth A S, Apte J S, Datta M R, Parikh M D, Lakdawalla P D, Ratnaparkhi S, Sharma U
Acta Psychiatr Belg. 1981 Jul-Aug;81(4):407-15.
Twenty-eight male chronic schizophrenic patients completed a 6 month treatment with a single weekly dose of 20 to 120 mg penfluridol, a new long- acting oral neuroleptic. Twenty-four patients showed significant improvement at the end of the trial period. Significant reduction in scores could be demonstrated in 21 out of 26 symptom variables. Central side-effects, reported by 19 patients, were mild and transient except in one patient who was withdrawn from the trial. Laboratory investigations and vital signs remained within normal limits.
28名男性慢性精神分裂症患者接受了为期6个月的治疗，每周单次服用20至120毫克五氟利多，这是一种新型长效口服抗精神病药物。24名患者在试验期结束时显示出显著改善。26个症状变量中有21个显示分数显著降低。19名患者报告的中枢副作用轻微且短暂，只有一名患者退出试验。实验室检查和生命体征均保持在正常范围内。
